159 related articles for article (PubMed ID: 9191121)
1. Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase.
Houslay MD; Scotland G; Erdogan S; Huston E; Mackenzie S; McCallum JF; McPhee I; Pooley L; Rena G; Ross A; Beard M; Peder A; Begg F; Wilkinson I; Yarwood S; Ackerman C; Houslay ES; Hoffman R; Engels P; Sullivan M; Bolger G
Biochem Soc Trans; 1997 May; 25(2):374-81. PubMed ID: 9191121
[No Abstract] [Full Text] [Related]
2. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5).
O'Connell JC; McCallum JF; McPhee I; Wakefield J; Houslay ES; Wishart W; Bolger G; Frame M; Houslay MD
Biochem J; 1996 Aug; 318 ( Pt 1)(Pt 1):255-61. PubMed ID: 8761480
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
4. Multiplicity within cyclic nucleotide phosphodiesterases.
Rybalkin SD; Beavo JA
Biochem Soc Trans; 1996 Nov; 24(4):1005-9. PubMed ID: 8968501
[No Abstract] [Full Text] [Related]
5. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition.
McPhee I; Yarwood SJ; Scotland G; Huston E; Beard MB; Ross AH; Houslay ES; Houslay MD
J Biol Chem; 1999 Apr; 274(17):11796-810. PubMed ID: 10206997
[TBL] [Abstract][Full Text] [Related]
6. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory effects of the novel phosphodiesterase IV inhibitor RP 73401.
Karlsson JA; Souness J; Webber S; Pollock K; Raeburn D
Int Arch Allergy Immunol; 1995; 107(1-3):425-6. PubMed ID: 7613200
[No Abstract] [Full Text] [Related]
8. The N-terminal alternately spliced regions of PDE4A cAMP-specific phosphodiesterases determine intracellular targeting and regulation of catalytic activity.
Houslay MD
Biochem Soc Trans; 1996 Nov; 24(4):980-6. PubMed ID: 8968496
[No Abstract] [Full Text] [Related]
9. Rolipram inhibition of phosphodiesterase-4 activation.
DiSanto ME; Heaslip RJ
Eur J Pharmacol; 1995 Jul; 290(2):169-72. PubMed ID: 8575533
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
11. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
Jacobitz S; McLaughlin MM; Livi GP; Burman M; Torphy TJ
Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
[TBL] [Abstract][Full Text] [Related]
12. Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast.
McHale MM; Cieslinski LB; Eng WK; Johnson RK; Torphy TJ; Livi GP
Mol Pharmacol; 1991 Feb; 39(2):109-13. PubMed ID: 1847489
[TBL] [Abstract][Full Text] [Related]
13. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.
Huston E; Lumb S; Russell A; Catterall C; Ross AH; Steele MR; Bolger GB; Perry MJ; Owens RJ; Houslay MD
Biochem J; 1997 Dec; 328 ( Pt 2)(Pt 2):549-58. PubMed ID: 9371714
[TBL] [Abstract][Full Text] [Related]
14. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cellular responses by hormones: role of cAMP specific, rolipram-sensitive phosphodiesterases.
Sette C; Vicini E; Conti M
Mol Cell Endocrinol; 1994 Apr; 100(1-2):75-9. PubMed ID: 8056162
[No Abstract] [Full Text] [Related]
16. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.
Bolger GB; Erdogan S; Jones RE; Loughney K; Scotland G; Hoffmann R; Wilkinson I; Farrell C; Houslay MD
Biochem J; 1997 Dec; 328 ( Pt 2)(Pt 2):539-48. PubMed ID: 9371713
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Hughes B; Howat D; Lisle H; Holbrook M; James T; Gozzard N; Blease K; Hughes P; Kingaby R; Warrellow G; Alexander R; Head J; Boyd E; Eaton M; Perry M; Wales M; Smith B; Owens R; Catterall C; Lumb S; Russell A; Allen R; Merriman M; Bloxham D; Higgs G
Br J Pharmacol; 1996 Jul; 118(5):1183-91. PubMed ID: 8818342
[TBL] [Abstract][Full Text] [Related]
18. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
19. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.
McPhee I; Pooley L; Lobban M; Bolger G; Houslay MD
Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):965-74. PubMed ID: 7575434
[TBL] [Abstract][Full Text] [Related]
20. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.
Barnette MS; Manning CD; Cieslinski LB; Burman M; Christensen SB; Torphy TJ
J Pharmacol Exp Ther; 1995 May; 273(2):674-9. PubMed ID: 7752069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
